2seventybio
Main focus: Novel cellular therapies for the treatment of cancer
Company stage: Clinical
Diseases: Cancer (undisclosed which programmes use gene editing)
Genome editing tool: megaTAL-based genome editing
Funding stage: Public (NASDAQ:TSVT)
Location: Cambridge, MA, USA
Website: https://www.2seventybio.com/
Pipeline: https://www.2seventybio.com/our-science
Gene editing Partnerships: Novo Nordisk
2seventy bio was recently formed as a spin-out company from bluebird bio. The company focuses on next generation cell-based therapies for the treatment of cancer. The company holds a priprietary megaTAL technology, which it applies for genomic engineering of its therapies. Currently, however, it is undisclosed which of the company's early phase programmes are actually incorporating the megaTAL technology.